Benzinga | Sep 20, 2021 07:05AM EDT

Fulcrum Therapeutics Announces Multiple Presentations During The Virtual Congress Of The World Muscle Society

Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters and presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) during the Virtual Congress of the World Muscle Society. These results highlight progress made in the development of losmapimod for the treatment of FSHD as well as imaging modalities for the management of FSHD.

"FSHD is a serious, relentless and debilitating disease for which there are currently no approved therapies," said Chris Morabito, MD, Fulcrum's chief medical officer. "The results from the Phase 2b ReDUX4 trial show clinically relevant benefit across multiple structural, functional and patient reported endpoints with losmapimod and represent a major advance for the potential treatment of FSHD. These data being presented support the benefit/risk of losmapimod as a disease-modifying therapy and its continued development. We remain on track to meet with regulators in the fourth quarter of this year and to provide an update on the clinical path forward in the first quarter of 2022."